Clearside Biomedical Inc CLSD.O:
CLEARSIDE BIOMEDICAL INC - ALL EMPLOYEES TO TRANSITION TO CONSULTING ROLES - SEC FILING
CLEARSIDE BIOMEDICAL INC - ESTIMATES $3.4 MILLION IN TERMINATION COSTS - SEC FILING
CLEARSIDE BIOMEDICAL INC: REDUCTION IN FORCE IS EXPECTED TO BE COMPLETED DURING Q3 OF 2025
Source text: [ID:n0000950170-25-096438]
Further company coverage: CLSD.O
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。